NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− breast cancer received anastrozole 1 mg daily for 4 weeks (cycle 0; with goserelin if premenopausal), followed by adding palbociclib (125 mg daily on days 1–21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67 > 10%, in which case patients went off study due to inadequate response. Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. Serial biopsies at baseline, C1D1, C1D15, and surgery were analyzed for Ki67, gene expression, and mutation profiles. The primary endpoint was complete cell cycle arrest (CCCA: central Ki67 ≤ 2.7%). Results: Fifty patients enrolled. The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P < 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. B) and PIK3CA status with activity observed across a broad range of clinicopathologic and mutation profiles. Ki67 recovery at surgery following palbociclib washout was suppressed by cycle 5 palbociclib. Resistance was associated with nonluminal subtypes and persistent E2F-target gene expression. Conclusions: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect. Clin Cancer Res; 23(15); 4055–65. ©2017 AACR.

[1]  J. Olson,et al.  Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[3]  Christopher A. Miller,et al.  Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation , 2016, Nature Communications.

[4]  Christopher A. Miller,et al.  Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers , 2016, Nature Communications.

[5]  A. Bardia,et al.  Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. , 2016, Breast.

[6]  Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 , 2016, Breast Cancer Research.

[7]  M. Ellis,et al.  Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[8]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[9]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet Oncology.

[10]  Obi L. Griffith,et al.  GenVisR: Genomic Visualizations in R , 2016, bioRxiv.

[11]  M. Ellis,et al.  Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. , 2016, Advances in experimental medicine and biology.

[12]  Obi L. Griffith,et al.  A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[13]  Obi L. Griffith,et al.  Genome Modeling System: A Knowledge Management Platform for Genomics , 2015, PLoS Comput. Biol..

[14]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[15]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[16]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[17]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[18]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[20]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[21]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[22]  D B Evans,et al.  Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole , 2010, The Pharmacogenomics Journal.

[23]  G. Mills,et al.  ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.

[24]  L. Giono,et al.  E2F1-Mediated Upregulation of p19INK4d Determines Its Periodic Expression during Cell Cycle and Regulates Cellular Proliferation , 2011, PloS one.

[25]  M. Ellis,et al.  Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors , 2011, Steroids.

[26]  J. Olson,et al.  Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[28]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[29]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[30]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[31]  J. Olson,et al.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.

[32]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[33]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[34]  A. Ashworth,et al.  Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.

[35]  Robert Gentleman,et al.  Using GOstats to test gene lists for GO term association , 2007, Bioinform..

[36]  H. Keselman,et al.  Multiple Comparison Procedures , 2005 .

[37]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[38]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[39]  R. Jove,et al.  Regulation of the Cyclin D3 Promoter by E2F1* , 2003, The Journal of Biological Chemistry.

[40]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[41]  J. Pollard,et al.  Progesterone Inhibits Estrogen-Induced Cyclin D1 and cdk4 Nuclear Translocation, Cyclin E- and Cyclin A-cdk2 Kinase Activation, and Cell Proliferation in Uterine Epithelial Cells in Mice , 1999, Molecular and Cellular Biology.

[42]  B. O’Malley,et al.  Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. , 1997, Endocrinology.

[43]  Woong Sun,et al.  Estrogen‐induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: Differential induction mechanism of cyclin D1 and D3 , 1997, Molecular reproduction and development.

[44]  L. Altucci,et al.  Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. , 1997, Endocrinology.

[45]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[46]  R. Weinberg,et al.  Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. , 1996, Oncogene.

[47]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[48]  S. van den Heuvel,et al.  Distinct roles for cyclin-dependent kinases in cell cycle control. , 1993, Science.

[49]  S. Weintraub,et al.  Retinoblastoma protein switches the E2F site from positive to negative element , 1992, Nature.

[50]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .